Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

By afschroeder • May 10, 2026

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatol Ther (Heidelb). 2026 May 9. doi: 10.1007/s13555-026-01774-2. Epub ahead of print. PMID: 42105056.

Tags: Dermatology, Investigator Global Assessment modified 2011 of the scalp (IGA mod 2011 [scalp]) score, Obesity, Olive View DoM, plaque psoriasis, Psoriasis Scalp Severity Index (PSSI), Publications, scalp psoriasis, tildrakizumab

Online vs In-Person Care for Atopic Dermatitis: A Randomized Clinical Trial

Armstrong AW, Roberts AM, Kostandy G, Choudhury F, Yee D, Luu M, Jones ME, Alizadeh ER, Cotliar J, Chren MM, Gelfand JM, Cockburn M, Doctor[...]

Alopecia Areata Is Associated with Increased Risk of Infertility in a Retrospective Cohort Study Using TriNetX

Podolsky AS, Goh C, Lipner SR. Alopecia Areata Is Associated with Increased Risk of Infertility in a Retrospective Cohort Study Using TriNetX. Skin Appendage Disord.[...]

Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis

Bchiri S, Bahrini K, Teles RMB, Alaya AB, Kamel HE, West J, Rategh K, Bouzekri A, Bousalem E, Ouni R, Fassatoui M, Mardassi H, Dekhil[...]